Alopecia Areata in Latin America: Where are We and Where are We Going?

被引:0
|
作者
Margarita M. Velásquez-Lopera
Natalia Hernández
Angela Marie Jansen
Angela Londoño García
Paula Carolina Luna
Mariana Rico-Restrepo
María del Mar Saez-de-Ocariz
María Margarita Tamayo-Buendía
Maria Cecilia Rivitti-Machado
机构
[1] Universidad de Antioquia,Centro de Investigaciones Dermatológicas CIDERM, Sección de Dermatología, Facultad de Medicina
[2] Dermatosoluciones SAS,Dermatology Department
[3] Americas Health Foundation,Department of Dermatology
[4] CES University,Departamento de Dermatologia
[5] Hospital Alemán,undefined
[6] Americas Health Foundation,undefined
[7] National Institute of Pediatrics,undefined
[8] Pontificia Universidad Javeriana,undefined
[9] Faculdade de Medicina da Universidade de São Paulo,undefined
来源
Dermatology and Therapy | 2023年 / 13卷
关键词
Alopecia areata; AA treatment; Dermatologic care in LA; Latin America; Targeted therapy in AA;
D O I
暂无
中图分类号
学科分类号
摘要
Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA’s AA management landscape and improve patient outcomes.
引用
收藏
页码:95 / 114
页数:19
相关论文
共 50 条